Analysis: Ventria on ITC win barring rHSA products

Last month, October 2022, the US International Trade Commission ( ITC) affirmed an administrative law judge’s (ALJ’s) finding that products containing recombinant human serum albumins (rHSAs) made by a Chinese company infringe a patent belonging to Ventria Bioscience.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

Analysis: Ventria on ITC win barring rHSA products

Editor's picks

Editor's picks

More features